(Q36219254)

English

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial (English)

1 reference

Europe PubMed Central

12 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

Soonmyung Paik

18

0 references

Sandra M. Swain

object named as

Sandra M Swain

19

0 references

Eleftherios P Mamounas

20

object named as

Eleftherios P Mamounas

1 reference

Europe PubMed Central

12 August 2017

author name string

Harry D Bear

1

1 reference

Europe PubMed Central

12 August 2017

Gong Tang

2

1 reference

Europe PubMed Central

12 August 2017

Priya Rastogi

3

1 reference

Europe PubMed Central

12 August 2017

Charles E Geyer

4

1 reference

Europe PubMed Central

12 August 2017

Qing Liu

5

1 reference

Europe PubMed Central

12 August 2017

André Robidoux

6

1 reference

Europe PubMed Central

12 August 2017

Luis Baez-Diaz

7

1 reference

Europe PubMed Central

12 August 2017

Adam M Brufsky

8

1 reference

Europe PubMed Central

12 August 2017

Rita S Mehta

9

1 reference

Europe PubMed Central

12 August 2017

Louis Fehrenbacher

10

1 reference

Europe PubMed Central

12 August 2017

James A Young

11

1 reference

Europe PubMed Central

12 August 2017

Francis M Senecal

12

1 reference

Europe PubMed Central

12 August 2017

Rakesh Gaur

13

1 reference

Europe PubMed Central

12 August 2017

Richard G Margolese

14

1 reference

Europe PubMed Central

12 August 2017

Paul T Adams

15

1 reference

Europe PubMed Central

12 August 2017

Howard M Gross

16

1 reference

Europe PubMed Central

12 August 2017

Joseph P Costantino

17

1 reference

Europe PubMed Central

12 August 2017

Norman Wolmark

21

1 reference

Europe PubMed Central

12 August 2017

publication date

10 August 2015

1 reference

Europe PubMed Central

12 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

12 August 2017

16

1 reference

Europe PubMed Central

12 August 2017

9

1 reference

Europe PubMed Central

12 August 2017

1037-1048

1 reference

Europe PubMed Central

12 August 2017

A systematic review of bevacizumab efficacy in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Anti-angiogenesis in cancer therapy: Hercules and hydra

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Bevacizumab and breast cancer: what does the future hold?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

The inhibition of tumor growth by tumor mass

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Allocation of patients to treatment groups in a controlled clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

1 October 2017

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

29 June 2018

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

29 June 2018

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

29 June 2018

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

22 September 2018

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624323

21 October 2018

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis and breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900041-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00041-8

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36219254&oldid=1984694362"